Orthocell has received a Research and Development (R&D) Tax Incentive refund of A$3.0 million for the financial year ended 30 June 2025.
The R&D Tax Incentive is an Australian Government program to support Australian companies to undertake R&D activities in Australia, under which eligible companies can receive cash rebates of up to 48.5% of eligible expenditure on R&D activities.
Orthocell CEO and MD, Paul Anderson, said,
“Receipt of our R&D tax refund of $3.0 million is a valuable non-dilutive enhancement to our cash position. This Australian Federal Government program should be applauded, as it provides meaningful economic incentives to drive investment in R&D. Our flagship nerve repair product, Remplir, which is now being commercialised throughout the Americas and Asia Pacific, is a tangible example of a product that has benefited from this program.
“We’re in a very strong position to continue to drive the commercialisation of Remplir for the benefit of our shareholders with $49.6 million in cash, no debt and no royalties payable.”